3.3.5 Basal Cell Carcinoma
Grading & Level of Importance: B
Basal cell epithelioma, basalioma.
Incidence in Europe: 450 to 500/100 000/year, most common skin malignancy.
Locally destructive malignant tumour derived from pluripotential epidermal stem cells, almost never metastasizes.
Aetiology & Pathogenesis
Risk factors: Skin types I and II (pale white and fair skin), UV exposure, immunosuppression, radiation, arsenic exposure/ingestion, specific genetic predisposition. Naevoid basal cell carcinoma syndrome (Gorlin-Goltz syndrome) is a genetic disease with predisposition for multiple basal cell carcinomas.
Signs & Symptoms
Pearly nodule with telangiectases, often raised border and central ulceration in superficial type (most common). Solid or nodular type. Sclerodermiform type infiltrating without sharp borders. Other types: cystic, rodent ulcer, metatypic (aggressive), pigmented.
Face, trunk, extremities. In contrast to squamous cell carcinoma, not restricted to sun exposed area.
No precursor lesions. Typing by histology.
Laboratory & other workups
Proliferation of progenitor cells in the basal layer of the epidermis and acroinfundibulum. Tumor cells invade different layers of the dermis. Peripheral palisading (darker row of cells at periphery), mitoses, single cell necrosis (apoptosis).
Slowly progressing. May be locally destructive of deeper tissues.
Recurrence rate after surgery or radiotherapy up to 5% within 5 years.
Depending on clinical and histological type.
Prevention & Therapy
Depends on the type, size and location. Excision of nodular and sclerodermic type because of recurrences in particular sclerosing tumours with micrographic control of margins; Radiation therapy in nodular types, cryosurgery. For superficial variants, also consider: cryosurgery, photodynamic therapy, topical 5-fluorouracil, immunomodulators (imiquimod), ablative laser with monitoring follow up. Advanced lesions: hedgehog inhibitors.
Further Images / DOIA
Be the first one to leave a comment!